Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 31;11:630. doi: 10.1038/s41467-020-14466-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a GFAP + astrocytes (green) in untreated and fibrinogen‐treated adult SVZ-derived NSPCs. Scale bar, 56 μm. Quantification of GFAP + astrocytes. (n = 3, mean ± s.e.m, unpaired Student’s t-test, ***P < 0.001). b Expression of GFAP mRNA in NSPCs. (n = 3, mean ± s.e.m, unpaired Student’s t-test, **P < 0.01). c Immunoblot for GFAP, Aqp4, Aldoc, and GAPDH in NSPCs 2 days after fibrinogen treatment. d Aldh1l1 + (green, top) and Aqp4 + (green, bottom) astrocytes in fibrinogen‐treated adult SVZ-derived NSPC cultures. (n = 3, representative images are shown). Scale bar, 67 μm. e GFAP + astrocytes (green) in fibrinogen‐treated hippocampus-derived NSPC cultures. Scale bar, 104 μm. Quantification of GFAP + astrocytes. (n = 2, performed in duplicate, mean ± s.e.m, unpaired Student’s t-test, *P < 0.05. f S100β (green) and GFAP (red) immunostainings in the SVZ at different timepoints after PT. White boxes indicate enlargement of S100β-GFAP + (right, top) and S100β + GFAP + (right, bottom) cells in the SVZ of uninjured and injured (PT day 3) mice, respectively. Scale bars, 40 μm, left and 7 µm, enlargement. Quantification of S100β + GFAP + cells per area (n = 4 mice, mean ± s.e.m, one-way ANOVA and Bonferroni’s multiple comparisons test, *P < 0.05). g EdU (grey), Thbs4 (green) and GFAP (red) immunostainings in the SVZ at 3 days after PT. White box indicates the enlargement of an EdU + GFAP + Thbs4 + DAPI + cell (right, bottom) in the SVZ 3 days after PT. Scale bar, 25 µm. Quantification of Thbs4 + GFAP + EdU + cells in the SVZ per area. (n = 4 mice, mean ± s.e.m, unpaired Student’s t-test, **P < 0.01). h immunolabeling for Thbs4 (green), S100β (red) and GFAP (gray) in the SVZ at 3 days after PT. White box indicating enlargement of a Thbs4 + S100β + GFAP + DAPI + cell in the SVZ 3 days after PT (n = 4 mice). Scale bar, 25 µm. i Scheme illustrating PT on ancrod-administered WT mice (top). S100β (red) and GFAP (green) immunostainings of the SVZ of ancrod-treated mice 6 days after PT. White boxes indicate enlargement of a S100β + GFAP + (top) and a S100β-GFAP + (bottom) cell in the SVZ of control and fibrinogen-depleted mice, respectively, 6 days after PT. Scale bars, 36 μm, left and 7 µm, enlargement. Quantification of S100β + GFAP + cells in the SVZ per area. (n = 4 mice, unpaired Student’s t-test, *P < 0.05). SVZ, subventricular zone.